CSF biomarkers and clinical progression of Parkinson disease. - Wikidata - wikimedia - TriplyDB

CSF biomarkers and clinical progression of Parkinson disease.

CSF biomarkers and clinical progression of Parkinson disease.

http://www.wikidata.org/entity/Q35106542

about

Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis Metabolomic biomarkers as strong correlates of Parkinson disease progression Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease.The role of biomarkers and imaging in Parkinson's disease.Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP.Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer.Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.Advances in Biomarker Research in Parkinson's Disease.Cognitive decline in Parkinson disease.Plasma α-synuclein predicts cognitive decline in Parkinson's disease.Proteomic studies associated with Parkinson's disease.Cerebrospinal Fluid Biomarkers for Huntington's Disease.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.Parkinson disease and cognitive impairment: Five new things.Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.Biomarkers in Neurodegenerative Diseases.Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.Why is there motor deterioration in Parkinson's disease during systemic infections-a hypothetical view.c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias.Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study.Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.Biomarkers for Parkinson's Disease: Recent Advancement.

P2860

Q26744782-C95A16F1-A426-4ADE-ACDB-50B3F4C38879 Q28082380-312BBAF7-9DCA-4170-AA26-3DA740CE83B5 Q29248111-795EC287-9856-4650-97AE-0B67C655E1FD Q30491906-8947BC26-2840-4152-8516-5DBD547E4A9D Q31041660-BA818D35-78D8-4A75-B593-F98F11D9C90B Q33917300-E44E92C1-5443-4294-8BBC-13C2666D621C Q35897340-7DA2F5C0-83FE-4C7E-9C49-3121B2E7A15A Q35969183-928C628E-B3F9-4D96-8A57-50DA0C68E958 Q36065012-AA378BB2-34F5-475A-8892-9F1A9EC768C3 Q36169215-5253BB37-DEE2-42E2-BF6C-04CD226E53E0 Q36277049-AE995FAC-8327-4B48-B1EA-A51E205F916E Q36789528-E19278D9-1D58-4204-ABDD-16800ECB1A7A Q37273088-239D48CD-CE04-43CB-9D59-31205773C0FB Q37345484-BC9C96EB-EB50-413F-ABB3-5941182D349F Q37494873-551D263D-72C4-4319-9798-DF75EB8E6577 Q37676938-7AD0B056-300A-4150-9F46-193362A44C63 Q38541943-F1FC85FF-B894-4869-A938-1F6FCF519F91 Q38603309-3462D3D5-7CF1-4F36-BC57-5A4C41644C35 Q38681599-149A357F-A4B2-4348-94CB-087974BF51B5 Q38751099-A90166EC-C775-4587-9474-DCEAA110546C Q38760749-A3AF1317-00C7-4B94-84C3-04B24DDC9049 Q38761409-0435C803-D7DD-4BA4-81AE-E293B9E5FAFD Q38794551-EF8354CA-1BA9-4D2B-B31F-D5A339F0918E Q38825497-8098243C-ED7C-4CFF-BBD3-0CC6C5F192A9 Q38853776-C5F88809-7743-41FF-9EBF-5E60096D7679 Q39009679-32C16F29-8B54-41B6-9D2E-41D9C5455D07 Q39010887-59C0EDE8-C1C2-4D4C-B009-D592D8D1198C Q39170813-BBFF62F6-2ACB-4B50-A7ED-38243B36A0E1 Q39366291-CDDCB285-4F47-4B4F-A4EB-2F8BFBAE4604 Q39413097-A830E11A-5E3E-46F2-83C3-5670A9144B44 Q39466212-89E0E2A4-FE53-41A4-BC90-1DF4B624372C Q40087267-B4BD66CF-D5A0-4340-9ED4-03F35A4234F1 Q42334435-B0953773-2CEE-4978-926D-285C0BF77261 Q47124745-112B93DD-D17D-4360-8061-E90549E30792 Q47338262-2EEFB65B-4083-4D18-8894-806FF1347D8B Q47923287-27CC08F3-193F-4EEF-984A-DD2B7E9649D4 Q47990737-6D13D475-0BB3-46D3-A1BB-70E164AEDAD3 Q48170789-754B3DA7-93D9-40BE-80B7-218DDB62959E Q48949617-52A48D64-4ADA-4185-9EF1-004E0243BBA0 Q49942492-4AE8FDA6-2008-4192-BA8F-3FB09CEEF23C

P2860

CSF biomarkers and clinical progression of Parkinson disease.

http://www.wikidata.org/entity/Q35106542

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

CSF biomarkers and clinical progression of Parkinson disease.

@ast

CSF biomarkers and clinical progression of Parkinson disease.

@en

type

label

CSF biomarkers and clinical progression of Parkinson disease.

@ast

CSF biomarkers and clinical progression of Parkinson disease.

@en

prefLabel

CSF biomarkers and clinical progression of Parkinson disease.

@ast

CSF biomarkers and clinical progression of Parkinson disease.

@en

P1433

Q35106542-64D7989B-6A51-4522-85D4-B2BB7582092C

P1476

Q35106542-1F433BD5-2BE6-40E0-A2A8-A452C51AA068

P2093

Q35106542-4AAC5F5B-B438-4EDA-960E-3F834028DF14

Q35106542-4C972135-9CC6-4344-B109-A60BD76D340B

Q35106542-8D1BE520-D775-430F-99C2-B8300A3E0B6C

Q35106542-C5C45250-D3D2-4648-B62A-2677297B26E0

P2860

Q35106542-03662A91-862F-4114-80CE-6F8FE92DA4A1

Q35106542-21C10702-F67D-4C88-B905-39B108137086

Q35106542-30C9E939-77A9-46D0-AAA8-1A1AA8D81397

Q35106542-35413532-3FDD-47AD-9CD3-898622E939BC

Q35106542-36773B2E-7CA0-4C35-84CA-99AE9DFCF225

Q35106542-37DF3CA8-0297-47C1-952B-6E454A885757

Q35106542-40344E64-9B3C-49D0-BC2D-47E3C581418B

Q35106542-420ED31C-35E8-4A81-8169-340F416F39B8

Q35106542-4C74E91A-91D1-43AB-BA37-E7D29B3101AD

Q35106542-558B6281-02BA-4526-A19D-46CD35A6DCF0

P304

Q35106542-FFEE47A8-E79D-4A38-AB6E-A7439FB3D0F1

P31

Q35106542-9E5B7052-6A99-4B1C-B97F-AAE7FAFE3D91

P356

Q35106542-D6AA0A64-347C-4ECA-BA60-657E3823E87D

P407

Q35106542-A5FCB911-5F35-4939-BBA6-54110CC195E1

P433

Q35106542-90184171-2ACF-45A4-94AD-D6FCC10448E7

P478

Q35106542-C1003944-6C84-4575-A0CD-54FE5ED8B597

P50

Q35106542-97DBA684-5228-4608-94B9-80E4961635CE

Q35106542-EB42C0A5-FF64-4517-B14B-33FC7522F72A

P577

Q35106542-FDE985CD-50C4-4F2A-9CB4-DA7DECACE549

P698

Q35106542-48D07B0D-F00A-46B5-9413-60DDFE02AE2A

P921

Q35106542-1CA3AB4D-FD2B-4A42-8E22-4C104CABB397

Q35106542-E32CF9A5-3F8F-4E40-80F3-A00C9C59CC15

P932

Q35106542-1CEBF5A6-9F89-41DF-A4D9-F27F527BE5A2

P356

WNL.0000000000001098

P1433

P1476

CSF biomarkers and clinical progression of Parkinson disease.

@en

P2093

Annika Öhrfelt

http://www.w3.org/2001/XMLSchema#string

Daniel Lindqvist

http://www.w3.org/2001/XMLSchema#string

Sara Hall

http://www.w3.org/2001/XMLSchema#string

Yulia Surova

http://www.w3.org/2001/XMLSchema#string

P2860

Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies

“Mini-mental state”

Parkinsonism: onset, progression and mortality

Distinct α-synuclein strains differentially promote tau inclusions in neurons

Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

Neuropathologic substrates of Parkinson disease dementia.

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Association of Parkinson disease risk loci with mild parkinsonian signs in older persons.

P304

57-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000001098

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

Henrik Zetterberg

P577

2014-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25411441

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4336091

http://www.w3.org/2001/XMLSchema#string